US-based Spineology has received US Food and Drug Administration (FDA) approval to use allograft bone with its Rampart Interbody fusion devices.

The Rampart Interbody fusion devices incorporate large graft windows to help healing, and a recently enhanced instrumentation system.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Further, the devices are available sterile packed, thereby removing the requirement for continual reprocessing, which cuts down costs for customers.

"In addition to reducing patient morbidity and enhancing surgical efficiency we expect this approval will provide Spineology with an excellent platform for delivery of our new Incite Cortical Fibers."

Spineology chief executive officer John Booth said: “This approval and our recent partnership expansion with Musculoskeletal Transplant Foundation (MTF) provides us the ability to pair MTF allografts with the Rampart family of interbody devices.

In addition to reducing patient morbidity and enhancing surgical efficiency we expect this approval will provide Spineology with an excellent platform for delivery of our new Incite Cortical Fibers.”

Incite Cortical Fibers are a versatile bone grafting solution.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The fibers provide an osteoconductive and inductive matrix, handling properties, in-situ expansion and placement options through a variety of delivery methods.

Spineology offers anatomy conserving spinal technologies for surgeons and patients.